title: ZD-6474. AstraZeneca.
abstract: ZD-6474, one of a series of inhibitors of vascular endothelial growth factor receptor tyrosine kinase, which also has activity against the epidermal growth factor receptor tyrosine kinase, is under development by AstraZeneca for the potential treatment of solid tumors. Phase II trials in non-small-cell lung cancer, small-cell lung cancer and myeloma were ongoing in January 2003.
authors.affiliation: Microvascular Research Laboratories, Department of Physiology, Preclinical Veterinary School, University of Bristol, Southwell Street, Bristol, BS2 8EJ, UK. Dave.Bates@bris.ac.uk
authors.forename: David
authors.initials: D
authors.lastname: Bates
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use*; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use*; D013678:Technology, Pharmaceutical / Q000379:methods
chemical_list: D015507:Drugs, Investigational; D004791:Enzyme Inhibitors; D010880:Piperidines; D011799:Quinazolines; C452423:vandetanib